{"timestamp": 1771609368.2548862, "value": {"ticker": "IKT", "company_name": "Inhibikase Therapeutics, Inc.", "short_name": "Inhibikase Therapeutics, Inc.", "sector": "Healthcare", "industry": "Biotechnology", "country": "United States", "market_cap": 211610992, "float_shares": 43653295, "shares_outstanding": 121267045, "short_ratio": 17.28, "short_percent_of_float": 0.1149, "shares_short": 8839652, "shares_short_prior": 6753894, "insider_percent_held": 0.08007, "institution_percent_held": 0.87088996, "total_cash": 77322216, "total_debt": 0, "total_revenue": 0, "revenue_growth": 0, "earnings_growth": 0, "profit_margins": 0.0, "gross_margins": 0.0, "operating_margins": 0.0, "debt_to_equity": 0, "current_ratio": 11.728, "book_value": 0.807, "price_to_book": 2.1623297, "operating_cashflow": -25616066, "free_cashflow": -13177324, "price": 1.745, "52w_high": 3.32, "52w_low": 1.33, "avg_volume": 621843, "avg_volume_10d": 852340, "full_time_employees": 15, "audit_risk": 8, "overall_risk": 9}}